This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Korbonits, M. Articles by Grossman, A. B. Search for Related Content PubMed PubMed Citation Articles by Korbonits, M. Articles by Grossman, A. B.

Expression of Phosphorylated p27^Kip1 Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors

Department of Endocrinology (M.K., H.S.C., G.K., S.J., Y.U., Z.K., A.B.G.), St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom; King’s College Hospital (P.E.H.), London SE15 5QN, United Kingdom; Center for Cell and Molecular Medicine (W.E.F.), University of Keele School of Postgraduate Medicine, Stoke-on Trent ST4 7QB, United Kingdom; and Department of Molecular Therapeutics (F.-X.C.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Address all correspondence and requests for reprints to: Prof. A. B. Grossman, Department of Endocrinology, St. Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, United Kingdom. E-mail: . A.B.Grossman{at}qmul.ac.uk

Abstract

The cyclin-dependent kinase inhibitor p27^Kip1 (p27) plays a pivotal role in controlling cell proliferation during development and tumorigenesis. p27 has been implicated in pituitary tumorigenesis in studies of knockout mice and in analyses of human pituitary tumor samples. In this study, we further explored the role of p27 in human pituitary tumors by measuring levels of phosphorylated p27 (P-p27), and also Jun activation domain-binding protein 1 (Jab1), which is thought to facilitate the phosphorylation and degradation of p27, in normal pituitary tissue (n = 21), pituitary adenomas (n = 75), and pituitary carcinomas (n = 10). The amount of p27 protein in corticotroph adenomas and pituitary carcinomas was much lower than that in normal pituitary tissue or other types of pituitary adenoma. Nuclear P-p27 protein levels were significantly decreased in the adenomas, compared with the normals, and were much lower in the carcinomas, compared with either normal pituitary tissue or pituitary adenomas. However, P-p27 levels in corticotroph adenomas were similar to normal pituitary tissue, thus demonstrating a greatly increased ratio of P-p27 to p27 specifically in corticotroph tumors. No difference was found in Jab1 protein levels in either corticotroph tumors or other pituitary adenomas, compared with normal tissue, but there was a small but significant increase in Jab1 levels in carcinomas. Corticotroph and metastatic tumors both showed a significantly higher Ki-67 labeling index than normal pituitary or other types of pituitary adenomas, and in general the Ki-67 labeling index was negatively correlated with p27 nuclear staining. The amount of p27 and Jab1 mRNA was positively correlated in all pituitary samples studied but did not correlate with the changes in immunostaining. Our findings suggest that in corticotroph tumors there is an accentuated phosphorylation of p27 into P-p27, possibly related to increased cyclin E expression, whereas both p27 and P-p27 are subject to increased degradation in pituitary carcinomas. Such variations in phosphorylation may play a role in pituitary tumorigenesis, but modulation of Jab1 is unlikely to be important in the pathogenesis of pituitary adenomas.

This article has been cited by other articles:

				J. Li, Y. Wang, C. Yang, P. Wang, D. K. Oelschlager, Y. Zheng, D.-A. Tian, W. E. Grizzle, D. J. Buchsbaum, and M. Wan Polyethylene Glycosylated Curcumin Conjugate Inhibits Pancreatic Cancer Cell Growth through Inactivation of Jab1 Mol. Pharmacol., July 1, 2009; 76(1): 81 - 90. [Abstract] [Full Text] [PDF]

				K. Horiguchi, M. Yamada, T. Satoh, K. Hashimoto, J. Hirato, M. Tosaka, S. Yamada, and M. Mori Transcriptional Activation of the Mixed Lineage Leukemia-p27Kip1 Pathway by a Somatostatin Analogue Clin. Cancer Res., April 15, 2009; 15(8): 2620 - 2629. [Abstract] [Full Text] [PDF]

				S. YABUUCHI, Y. KATAYOSE, A. ODA, M. MIZUMA, S. SHIRASOU, T. SASAKI, K. YAMAMOTO, M. OIKAWA, T. RIKIYAMA, T. ONOGAWA, et al. ZD1839 (IRESSA(R)) Stabilizes p27Kip1 and Enhances Radiosensitivity in Cholangiocarcinoma Cell Lines Anticancer Res, April 1, 2009; 29(4): 1169 - 1180. [Abstract] [Full Text] [PDF]

				V. Quereda and M. Malumbres Cell cycle control of pituitary development and disease J. Mol. Endocrinol., February 1, 2009; 42(2): 75 - 86. [Abstract] [Full Text] [PDF]

				M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292. [Abstract] [Full Text] [PDF]

				M. A. Kouvaraki, A. L. Korapati, G. Z. Rassidakis, L. Tian, Q. Zhang, P. Chiao, L. Ho, D. B. Evans, and F. X. Claret Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. Cancer Res., September 1, 2006; 66(17): 8581 - 8589. [Abstract] [Full Text] [PDF]

				E. Hubina, A. M Nanzer, M. R Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M. R. Terreni, S. Khalaf, S. Jordan, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol., August 1, 2006; 155(2): 371 - 379. [Abstract] [Full Text] [PDF]

				W. Oh, E.-W. Lee, Y. H. Sung, M.-R. Yang, J. Ghim, H.-W. Lee, and J. Song Jab1 Induces the Cytoplasmic Localization and Degradation of p53 in Coordination with Hdm2 J. Biol. Chem., June 23, 2006; 281(25): 17457 - 17465. [Abstract] [Full Text] [PDF]

				K. S. Richardson and W. Zundel The Emerging Role of the COP9 Signalosome in Cancer Mol. Cancer Res., December 1, 2005; 3(12): 645 - 653. [Abstract] [Full Text] [PDF]

				M Musat, M Korbonits, B Kola, N Borboli, M R Hanson, A M Nanzer, J Grigson, S Jordan, D G Morris, M Gueorguiev, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 423 - 433. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]

				Y. Dong, L. Sui, Y. Watanabe, F. Yamaguchi, N. Hatano, and M. Tokuda Prognostic Significance of Jab1 Expression in Laryngeal Squamous Cell Carcinomas Clin. Cancer Res., January 1, 2005; 11(1): 259 - 266. [Abstract] [Full Text] [PDF]

				K. N. Farrow, A. P. Bradford, J. J. Tentler, and A. Gutierrez-Hartmann Structural and Functional Analysis of the Differential Effects of c-Jun and v-Jun on Prolactin Gene Expression Mol. Endocrinol., October 1, 2004; 18(10): 2479 - 2490. [Abstract] [Full Text] [PDF]

				M. A. Kouvaraki, G. Z. Rassidakis, L. Tian, R. Kumar, C. Kittas, and F.-X. Claret Jun Activation Domain-binding Protein 1 Expression in Breast Cancer Inversely Correlates with the Cell Cycle Inhibitor p27Kip1 Cancer Res., June 1, 2003; 63(11): 2977 - 2981. [Abstract] [Full Text] [PDF]

				G. Z. Rassidakis, F.-X. Claret, R. Lai, Q. Zhang, A. H. Sarris, T. J. McDonnell, and L. J. Medeiros Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma Clin. Cancer Res., March 1, 2003; 9(3): 1121 - 1128. [Abstract] [Full Text] [PDF]